Examkin

Question

Difficulty: MediumPharmacologic Interventions

A 62-year-old man comes to the clinic due to a 24-hour history of severe pain, redness, and swelling in his right great toe. The pain is so severe that he cannot tolerate the weight of a bedsheet. His medical history is significant for ischemic cardiomyopathy with a left ventricular ejection fraction of 25%, type 2 diabetes mellitus, and stage 4 chronic kidney disease. Current medications include carvedilol, sacubitril-valsartan, empagliflozin, furosemide, and insulin glargine.

Vital signs show a blood pressure of 110/70 mm Hg, heart rate of 68/min, and temperature of 37.1°C (98.8°F). Physical examination reveals an erythematous, warm, swollen, and exquisitely tender right first metatarsophalangeal joint. The jugular venous pressure is estimated at 10 cm H2O. There is 2+ bilateral lower extremity pitting edema.

Laboratory studies show:
Serum creatinine: 2.8 mg/dL (baseline 2.7 mg/dL)
Estimated glomerular filtration rate: 22 mL/min/1.73 m²
Serum uric acid: 9.4 mg/dL

Which of the following is the most appropriate pharmacologic intervention for this patient's current joint symptoms?

  1. Intra-articular triamcinolone acetonideAnswer
  2. B
    Oral indomethacin
  3. C
    Oral colchicine
  4. D
    Oral allopurinol
  5. E
    Oral prednisone

Answer

Intra-articular triamcinolone acetonide
The correct answer is intra-articular triamcinolone acetonide. This patient presents with an acute gout flare in a single joint (podagra). The management of acute gout typically involves NSAIDs, colchicine, or systemic glucocorticoids. However, this patient's severe comorbidities preclude the use of these systemic agents. He has stage 4 chronic kidney disease (eGFR 22 mL/min), which contraindicates the use of NSAIDs due to the risk of worsening renal failure, and makes colchicine highly dangerous due to the risk of toxic accumulation. Furthermore, he has evidence of actively decompensated heart failure with reduced ejection fraction (elevated JVP and pitting edema); NSAIDs and systemic glucocorticoids (like oral prednisone) promote sodium and water retention, which could precipitate a severe cardiopulmonary decompensation. For a monoarticular flare in a patient with these systemic contraindications, an intra-articular glucocorticoid injection is the safest and most effective intervention.

Step-by-Step Solution

1
Diagnose the acute presentation.
The patient is experiencing an acute monoarticular gout flare (podagra) of the first metatarsophalangeal joint.
Sudden onset of severe pain, erythema, and swelling in a typical joint, combined with hyperuricemia, strongly points to acute gout.
2
Evaluate comorbidities for pharmacologic contraindications.
The patient has stage 4 chronic kidney disease and actively decompensated heart failure (indicated by elevated JVP and pitting edema).
Standard gout therapies have significant systemic toxicities that must be weighed against the patient's underlying organ dysfunction.
3
Select the safest, most effective targeted therapy.
Intra-articular triamcinolone acetonide is selected.
Local glucocorticoid injection provides potent anti-inflammatory effects for a single joint without the systemic risks of fluid retention, renal toxicity, or glycemic derangement.

Key Concept

In patients with acute monoarticular gout and significant comorbidities (such as advanced CKD and decompensated heart failure) that contraindicate systemic NSAIDs, colchicine, and oral corticosteroids, intra-articular glucocorticoid injection is the treatment of choice.
Estimated Time:1m 30s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic